Faeth Therapeutics (FTH) Research & Development (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Research & Development came in at $18.0 million in Q1 2026, up 382.07% YoY from $3.7 million in Q1 2025, and up 729.04% on a QoQ basis from $2.2 million in Q4 2025.
Faeth Therapeutics (FTH) Research & Development (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Research & Development data on file, last reported at $18.0 million in Q1 2026.
- Quarterly Research & Development rose 382.07% year-over-year to $18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.2 million (up 44.49% YoY) and the FY2025 annual result came in at $11.0 million, down 41.16% from the prior year.
- Research & Development grew to $18.0 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $18.0 million in Q1 2026 to a low of $2.2 million in Q4 2025.
- A 5-year average of $5.7 million and a median of $4.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 58.45% — and 2026, when it surged 382.07%.
- Tracing FTH's Research & Development over 5 years: stood at $7.3 million in 2022, then plunged by 38.83% to $4.5 million in 2023, then slipped by 0.09% to $4.5 million in 2024, then plunged by 51.75% to $2.2 million in 2025, then surged by 729.04% to $18.0 million in 2026.
- The last three Research & Development figures came in at $18.0 million (Q1 2026), $2.2 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 97.90 Mn |
| 10 | Faeth Therapeutics | 179.40 Mn | 179.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.18 Mn |
| Mar 31, 2026 | 17.96 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 2.54 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 4.49 Mn |
| Sep 30, 2024 | 4.64 Mn |
| Jun 30, 2024 | 4.58 Mn |
| Mar 31, 2024 | 4.92 Mn |
| Dec 31, 2023 | 4.49 Mn |
| Sep 30, 2023 | 3.82 Mn |
| Jun 30, 2023 | 4.78 Mn |
| Mar 31, 2023 | 5.20 Mn |
| Dec 31, 2022 | 7.35 Mn |
| Sep 30, 2022 | 9.19 Mn |
| Jun 30, 2022 | 6.39 Mn |
| Mar 31, 2022 | 7.46 Mn |
| Dec 31, 2021 | 5.96 Mn |
| Sep 30, 2021 | 6.44 Mn |